OTC Monograph Drug User Fee Transparency Act

[AI summary unavailable — showing source text] [Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [S. 2513 Introduced in Senate (IS)] <DOC> 119th CONGRESS 1st Session S. 2513 To amend the Federal Food, Drug, and Cosmetic Act with respect to transparency and reporting regarding over-the-counter drug monograph activities, and for other purposes. _______________________________________________________________________ IN THE SENATE OF THE UNITED STATES July 29, 2025 Mr. Kaine introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions _______________________________________________________________________ A BILL To amend the Federal Food, Drug, and Cosmetic Act with respect to transparency and reporting regarding over-the-counter drug monograph activities, and for other purposes. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1. SHORT TITLE. This Act may be cited as the ``OTC Monograph Drug User Fee Transparency Act''. SEC. 2. OTC MONOGRAPH DRUG PERFORMANCE REPORTS. (a) Performance Report.--Section 744N of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379…